The Effect of XXXX (Iressa(R)) in the Treatment of Refractory Non Small Cell Lung Cancer.

@entity1 @entity137 @entity390 @entity417 @entity4562 @entity882 @entity1398
PURPOSE: The aim of this study was to evaluate the efficacy and the safety of @entity4562 (Iressa(R)) as a 3rd or 4th line chemotherapy regimen in NSCLC @entity1 who are refractory to a previous chemotherapy regimen. MATERIALS AND METHODS: Twenty-five @entity1 who were refractory to previous chemotherapy were selected for this study. The eligible @entity1 had an ECOG performance status of 0 to 2, and an appropriate end organ function. @entity4562 (Iressa(R))250 mg/d was orally administered until the @entity1 experienced disease progression or unacceptable @entity137 . RESULTS: Twenty-five @entity1 were analyzed. The median age of the @entity1 was 57 years. The response rate was 12.0% with partial responses in 3 @entity1 . Fourteen @entity1 (56%) remained in the stable disease state and 8 @entity1 progressed. The median overall survival was 9.0 months (95% CI 6.7~11.2). The median progression free survival was 3 months (95% CI 2.2~3.8). Hematological @entity137 of grade 3 or 4 @entity1398 , @entity417 and @entity882 were absent. Non-hematological @entity137 were grade 2 or 3 skin rashes in 10 (40.0%) @entity1 and 1 (4.0%) @entity1 and grade 3 @entity390 in 3 (12.0%) @entity1 . No @entity1 failed to continue chemotherapy due to any drug-related adverse events. CONCLUSION: The results suggest that @entity4562 (Iressa(R)) monotherapy is effective and tolerable as a 3rd or 4th line salvage treatment for NSCLC @entity1 refractory to previous chemotherapy regimens.
